Why Sundial, Canopy Growth, and Green Thumb Stocks Dropped Today By Rich Smith - Oct 1, 2021 at 1:41PM Key Points Bank of America downgraded Canopy Growth stock Friday on concerns about the cannabis company's path to profitability. Other marijuana stocks are falling alongside Canopy.
Why is Canopy Growth Stock losing money?
Apr 08, 2022 · Source. Headline. A number of insiders bought Costa Group Holdings Limited (ASX:CGC) stock last year, which is great news for shareholders. finance.yahoo.com - April 9 at 8:42 PM. Canopy Growth (NASDAQ:CGC) Stock Price Down 6.4%. americanbankingnews.com - April 7 at 2:02 PM.
Is Canopy Growth (CGC) stock down 57% over six months?
Oct 01, 2021 · As of 12:10 p.m. Friday, Canopy Growth shares were down by 4.9%, shares of Sundial were down by 2.5%, and Green Thumb Industries was off by 2.3%. Oh well. No one ever accused investors of being ...
What is the EPs rating of Canopy Growth Stock?
Financial Failure Makes Canopy Growth Uninvestable Now Canopy Growth (CGC) stock might tempt some bottom-fishers to scoop up shares in hopes …
Why is Canopy Growth’s acquisition of Acreage holdings so important?
Oct 03, 2021 · So what. The September move only added to the company's 2021 declines. Year to date, Canopy shares are down more than 45%. Last month's decline didn't stem from any company-specific news. In fact ...
Why is Canopy Growth stock dropping?
Mounting losses and difficulty growing revenue are just a few of the reasons Canopy Growth stock has struggled to do well in recent years. It isn't alone in its challenges, as other Canadian pot stocks are down big in the past year.Jan 12, 2022
Is Canopy Growth a good stock to buy right now?
So, right now, WEED stock trades at a price-to-sales ratio of 7.5 times while still being nowhere near breaking even. Therefore, I'd have to say Canopy Growth stock is still considerably overvalued and a higher-risk investment.Jan 10, 2022
Is there any hope for Canopy Growth?
Canopy has been seeing declining revenue the last few quarters. Investors hope 2022 could be brighter for the company. But its recent third quarter (ended Dec.Feb 24, 2022
What is the outlook for Canopy Growth?
Stock Price Forecast The 15 analysts offering 12-month price forecasts for Canopy Growth Corp have a median target of 7.10, with a high estimate of 13.41 and a low estimate of 5.52. The median estimate represents a -0.04% decrease from the last price of 7.10.
Is Canopy Growth in the US?
Canopy Growth management has focused on a strategy of absorbing financial losses short term in order to dramatically expand its operations and sales in the emerging recreational and medical cannabis markets in the U.S, Canada, and globally.
Can a canopy recover?
Recovery potential is weak but still present A return to high double-digit revenue growth may lift Canopy Growth's stock price. However, Wall Street analysts currently project a low and disheartening 13.9% revenue growth for the fiscal year 2022, which ends in March next year.Sep 21, 2021
Why is Canopy Growth rising?
Canopy Growth's shares were jumping Wednesday after the Canadian cannabis company reported higher-than-expected revenue as sales of its other products helped offset a year-over-year decline in Canadian sales of marijuana.Feb 9, 2022
What companies does Canopy Growth own?
The company was renamed to Canopy Growth Corp. in September 2015 with two established brands: Tweed Inc. and Bedrocan Canada Corp. Specifically, CGC is the parent company of licensed cannabis producers Tweed Inc., Tweed Farms Inc., Spectrum Cannabis., as well as newly acquired companies.
Is Canopy Growth a Buy Sell or Hold?
Bottom line: Canopy Growth stock is not in a buy zone, so it isn't a buy right now. IBD's research shows investors would be better off looking for stocks with stronger fundamentals and that are closer to their highs.
What is the target price for CGC?
Analyst Price Target on CGC Based on 10 Wall Street analysts offering 12 month price targets for Canopy Growth in the last 3 months. The average price target is $8.00 with a high forecast of $13.53 and a low forecast of $5.97. The average price target represents a 16.11% change from the last price of $6.89.
Is Cron a buy or sell?
Out of 4 analysts, 0 (0%) are recommending CRON as a Strong Buy, 0 (0%) are recommending CRON as a Buy, 3 (75%) are recommending CRON as a Hold, 0 (0%) are recommending CRON as a Sell, and 1 (25%) are recommending CRON as a Strong Sell. What is CRON's earnings growth forecast for 2022-2024?
Any Reason To Buy Canopy Growth After Signs Of Institutional Buying?
Canopy Growth has struggled. But some IBD data has signaled more institutional support. So is there any reason to buy CGC stock now?
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Schwazze completed $75 million acquisition. Israeli medical cannabis company InterCure reported its preliminary Q4 financial results. Cannabis REIT Chicago Atlantic lent $34 million to FarmaceuticalRX. Red White & Bloom closed the acquisition of Michigan marijuana operator PharmaCo.
Are Any Marijuana Stocks On U.S. Exchanges Buys After Canopy, Aurora Earnings?
Are any Canadian marijuana stocks buys now, after Canopy Growth and Aurora Cannabis reported earnings?
Humble & Fume: Windship Distribution Subsidiary Boosted By Supply Agreement With BRNT
By ExecEdge Editorial Staff Humble & Fume (CNSX: HMBL) has added another stable partner, as it continues to expand its product portfolio across North America.
Stocks: CVS slips after earnings beat, Canopy Growth rallies, Rivian rebounds
Yahoo Finance's Ines Ferre breaks down trending stocks: CVS, Canopy Growth, and Rivian.
Canopy Growth Stock Jumps After Earnings, Despite Slowing Marijuana Sales
Canopy's BioSteel sports-hydration business and Storz & Bickel, its medical vaporizer arm, generated record quarterly revenue.
Cullen Buys iShares MSCI EAFE ETF, Vanguard Growth ETF, Vanguard FTSE Emerging Markets ETF, ..
Investment company Cullen (Current Portfolio) buys iShares MSCI EAFE ETF, Vanguard Growth ETF, Vanguard FTSE Emerging Markets ETF, Schwab US Dividend Equity ETF, Lennar Corp, sells Chevron Corp, , Aon PLC, Pinterest Inc, iShares Core S&P Mid-Cap ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cullen..
NASDAQ: CGC
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What happened
Volatility in the cannabis sector shouldn't be a surprise to investors, but one popular company experienced a significant move last month. Shares of Canadian marijuana company Canopy Growth ( CGC -5.52% ) dropped 19.6% in September, according to data from S&P Global Market Intelligence.
So what
The September move only added to the company's 2021 declines. Year to date, Canopy shares are down more than 45%. Last month's decline didn't stem from any company-specific news. In fact, in an investor presentation on Sept.
Now what
But Canopy investors should also be focused more on the long-term picture. That includes a path toward legalization and subsequent sales growth in the United States. The company is already launching new products in the U.S. market, including a cannabidiol (CBD) vape product announced in September.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
Rising losses
One big reason why Canopy Growth keeps falling is because it keeps losing money quarter after quarter. At the start of this article, I did mention an earnings beat in the most recent quarter, but I’ll address that shortly. It wasn’t really quite the beat that it appeared to be at first glance.
U.S. legalization taking a long time
A final factor contributing to Canopy Growth’s slide is the fact that U.S. legalization is taking an awfully long time. Canadian cannabis legalization is almost three years in the past at this point. The revenue boost that came from that has already occurred, and now deceleration is underway.
The cannabis producer reported dismal fourth-quarter results
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of Canopy Growth ( NASDAQ:CGC) were crashing 18.5% lower as of 10:01 a.m. EDT on Friday. The steep drop came after the Canadian cannabis producer announced its fiscal 2020 fourth-quarter and full-year results before the market opened.
So what
Any company that misses Wall Street's expectations as badly as Canopy did is going to experience repercussions. It's important to understand why Canopy underperformed so much, though.
Now what
There could be even higher volatility for the marijuana stock moving forward. Canopy withdrew its previous milestones for achieving positive adjusted EBITDA and net income. That's certainly not good news for investors who were hoping the company would establish a clear pathway to profitability.
Canadian marijuana stocks are reversing course Monday after last week's industrywide surge higher
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
What happened
Thanks to rising tensions in Ukraine and the Federal Reserve's mixed messaging on interest rates, Canadian marijuana stocks are having another tough go of it today. As of 2:55 p.m.
So what
Why can't Canopy Growth, Hexo, and OrganiGram maintain any upward momentum? Three big issues are weighing on these stocks at the moment. First off, the hype surrounding the possible legalization of cannabis at the federal level in the U.S.
Now what
Are any of these stocks worth picking up on today's pullback? Among these three names, OrganiGram comes across as the most compelling buy. By sticking to its business plan focused on growing high-quality cannabis, the company has made significant progress toward its key operating goals over the past two years.
What is the market cap of CGC?
CGC stock has a market cap of around $7.6 billion, making it the No. 1 marijuana stock by value. However, the EPS Rating of Canopy Growth stock, a measure of profit growth on a scale of 1 to 99, is 18. Earnings growth is a hallmark of top stocks.
What is an IBD buy point?
IBD advises investors to buy stocks only after they set up in proper bases and rise above certain resistance levels, called buy points . But for Canopy, no such base pattern has formed, meaning no new buy point is in play.
Who is the CEO of canopy?
Canopy has closed facilities and made aggressive cost cuts under the leadership of CEO David Klein, after his predecessor, Bruce Linton, raced to expand domestically and internationally.
What happened
Shares of leading Canadian marijuana grower Canopy Growth ( NASDAQ:CGC) declined 21.5% in 2019, according to data from S&P Global Market Intelligence. That might not sound so terrible, but when you consider that the S&P 500 returned 31.5% last year, that means Canopy stock underperformed the market by 53%.
So what
Canopy Growth stock started 2019 on an incredibly strong note. By the end of April, it was up a whopping 88%, or almost five times the S&P 500's 18.3% return. Along with general bullishness in the cannabis space, here are the main company-specific catalysts that lit a fire under Canopy stock in the first four months of last year:
Now what
Tomorrow starts the Klein era at Canopy Growth. Investors should get to hear from him next month. While Canopy hasn't yet set a date for the release of its third-quarter results for fiscal 2020, it should be about mid-February. Wall Street is expecting revenue growth of 24.6% year over year and the loss per share to widen by 26.3%.